Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.
Sezer O, Beksac M, Hajek R, Sucak G, Cagirgan S, Linkesch W, Meltem Akay O, Gülbas Z, Nahi H, Plesner T, Snowden JA, Timurağaoğlu A, Dechow T, Lang A, Tuğlular T, Drach J, Armbrecht G, Potamianou A, Couturier C, Olie RA, Feys C, Allietta N, Terpos E.
Sezer O, et al. Among authors: linkesch w.
Br J Haematol. 2017 Jul;178(1):61-71. doi: 10.1111/bjh.14637. Epub 2017 Apr 6.
Br J Haematol. 2017.
PMID: 28382618
Free article.
Clinical Trial.